Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors.

Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors.
复制标题

DOI:
10.1038/ja.2014.133
复制
发表时间:
2015-04
期刊:
The Journal of antibiotics
影响因子:
--
通讯作者:
--
中科院分区:
其他
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

Capuramycin(1)及其类似物是强效的转位酶I(MurX/MraY)抑制剂。在我们对卡普霉素类似物抗M.在对结核病(Mtb)的研究中,我们首次观察到卡普霉素类似物UT-01320(3)在低氧条件下以低浓度杀死非复制(休眠)Mtb,而选择性MurX抑制剂在需氧条件下仅杀死复制Mtb。有趣的是,即使在高浓度下,3也没有表现出MurX酶抑制活性,然而,3抑制细菌RNA聚合酶,IC 50值为100-150 nM范围。一种新的RNA聚合酶抑制剂3与MurX抑制剂SQ 641(2)(一种有前途的临床前TB药物)显示出强烈的协同作用。
Capuramycin (1) and its analogs are strong translocase I (MurX/MraY) inhibitors. In our SAR studies of capuramycin analogs against M. tuberculosis (Mtb), we observed for the first time that a capuramycin analog, UT-01320 (3) killed non-replicating (dormant) Mtb at low concentrations under low-oxygen conditions, whereas selective MurX inhibitors killed only replicating Mtb under aerobic conditions. Interestingly, 3 did not exhibit MurX enzyme inhibitory activity even at high concentrations, however, 3 inhibited bacterial RNA polymerases with the IC50 values of 100-150 nM range. A new RNA polymerase inhibitor 3 displayed strong synergistic effects with a MurX inhibitor SQ 641 (2), a promising preclinical TB drug.
DOI: 10.1093/jac/dkh417
发表时间: 2004-10-01
影响因子: 5.2
作者:
Koga, T;Fukuoka, T;Hirota, T
通讯作者: Hirota, T
为什么要治愈结核病需要长期治疗?
DOI: 10.1371/journal.pmed.0040120
发表时间: 2007-03
期刊: PLOS MEDICINE
影响因子: 15.8
作者:
Connolly, Lynn E.;Edelstein, Paul H.;Ramakrishnan, Lalita
通讯作者: Ramakrishnan, Lalita
DOI: 10.1099/mic.0.033084-0
发表时间: 2010-01-01
期刊: MICROBIOLOGY-SGM
影响因子: 2.8
作者:
Gengenbacher, Martin;Rao, Srinivasa P. S.;Dick, Thomas
通讯作者: Dick, Thomas
DOI: 10.1016/j.ab.2003.08.038
发表时间: 2004-01-15
影响因子: 2.9
作者:
Kuhlman, P;Duff, HL;Galant, A
通讯作者: Galant, A